TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Sanara MedTech ( (SMTI) ) is now available.
On May 22, 2025, Sanara MedTech Inc. held its Annual Meeting of Shareholders, where a total of 6,781,075 shares were represented. During the meeting, the election of eight directors to the Board and the ratification of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were approved by the shareholders. Additionally, on May 27, 2025, the company updated its investor presentation on its website, emphasizing the importance of monitoring their Investor Relations section for material information.
The most recent analyst rating on (SMTI) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.
Spark’s Take on SMTI Stock
According to Spark, TipRanks’ AI Analyst, SMTI is a Neutral.
Sanara MedTech’s overall stock score reflects its strong revenue growth and product sales expansion, which are significant positives. However, these are balanced by ongoing concerns in profitability, cash flow management, and increased leverage. The technical analysis suggests neutral market momentum, and the valuation is challenged by negative earnings. The earnings call highlights both growth opportunities and financial challenges, shaping a mixed overall outlook.
To see Spark’s full report on SMTI stock, click here.
More about Sanara MedTech
Average Trading Volume: 27,975
Technical Sentiment Signal: Sell
Current Market Cap: $273.6M
Find detailed analytics on SMTI stock on TipRanks’ Stock Analysis page.